Omeros: Omeros to activate site for Phase III programme of zaltenibart for PNH
Omeros has announced the activation of clinical trial sites for enrolment is now in progress for its Phase III programme of zaltenibart. The post Omeros to activate site for Phase III programme of zaltenibart for PNH appeared first on Clinical Trials Arena.
Read full article »
Omeros is a Wasington-based biopharmaceutical company that researches and develops small-molecule and protein therapeutics for the treatment of inflammation and CNS disorders.
Read more